Get started
Author

Marcos Rezende Teixeira

Observed names: M R D J Teixeira, M. Teixeira, Marcos Rezende de Jesus Teixeira, Maria Fernanda Botelho Teixeira
ORCID: 0009-0000-1202-2838
Observed ORCID: 0009-0000-1202-2838
OpenAlex ID: A5113882529
Real-world comparison of the impact of adjuvant capecitabine in women with high-risk triple-negative breast cancer after neoadjuvant chemotherapy
2019 · M.T.S. Vilbert, M.P. Corassa, et al. · Annals of Oncology · 3
Local therapy in advanced melanoma after immune checkpoint inhibitors aiming to achieve complete response
2023 · Milton José de Barros e Silva, Marcos Rezende Teixeira, et al. · Journal of Cancer Research and Therapeutics · 1
FDG-PET/CT response and outcome of neoadjuvant immunotherapy for clinical stage III melanoma.
2021 · Milton Jose De Barros E. Silva, Caio Dabbous Liz, et al. · Journal of Clinical Oncology · 1
18F-FDG-PET/CT response assessment in patients with advanced melanoma treated with combination of low-dose ipilimumab and anti-PD1: A real-world experience.
2021 · Caio Dabbous Liz, Marcos Rezende Teixeira, et al. · Journal of Clinical Oncology · 1
Discordant response comparing 18F-FDG PET/CT with response assessment by RECIST in patients with advanced melanoma treated with immune checkpoint blockade.
2020 · Milton Jos De Barros E Silva, Marcos Rezende Teixeira, et al. · Journal of Clinical Oncology · 1
Bone metastasis as an independent prognostic factor for survival in patients with advanced melanoma treated with immune checkpoint blockade.
2020 · Marcos Rezende Teixeira, Milton Jos De Barros E Silva, et al. · Journal of Clinical Oncology · 1
Homologous Recombination Deficiency as a Biomarker for Chemoimmunotherapy Benefit in Advanced Biliary Tract Cancer: A Multicenter Retrospective Cohort Study
2026 · Oluseyi Abidoye, Heidi Kosiorek, et al. · SSRN Electronic Journal
Lactate dehydrogenase as an independent prognostic factor for survival in patients with advanced melanoma treated with immune checkpoint blockade
2025 · Marcos Rezende de Jesus Teixeira, Milton Jose de Barros, et al. · Brazilian Journal of Oncology
Bone Metastasis as an Independent Prognostic Factor for Survival in Patients With Advanced Melanoma Treated With Immune Checkpoint Blockade
2022 · Marcos Rezende de Jesus Teixeira, Milton Jose de Barros e Silva, et al. · Brazilian Journal of Oncology
18f-fdg-pet/ct Response Assessment in Patients With Advanced Melanoma Treated With Combination of Low-dose Ipilimumab and Anti-pd1: a Real World Experience
2021 · Caio Dabbous De Liz, Marcos Rezende Teixeira, et al. · Brazilian Journal of Oncology
1059P 18F-FDG-PET/CT response assessment in patients with advanced melanoma treated with combination of low-dose ipilimumab and anti-PD1: A real-world experience
2021 · C.D. De Liz, M. Teixeira, et al. · Annals of Oncology
PDF
Standard-dose Nivolumab in Combination With Reduced-dose Ipilimumab for Patients With Advanced Melanoma
2019 · Natasha Carvalho Pandolfi, Marcos Rezende Teixeira, et al. · Brazilian Journal of Oncology
Prognostic Factors of Human Epidermal Growth Factor Receptor 2- Positive (her2+) Breast Cancer Patients With Brain Metastasis in the Era of Targeted Therapy
2019 · Julia Carole Medeiros de Melo, Tiago Cordeiro Felismino, et al. · Brazilian Journal of Oncology
Works count: 13
Citation count: 7
H-index: 1
I10-index:
Year
Topic
Type